Resonant acquires Creapharm Bioservices to expand European biobanking
AI Summary- Resonant Clinical Solutions acquired Creapharm Bioservices from Myonex.
- 46% of Phase I to III trials launched in 2024 involved non-small-molecule modalities.
- Creapharm will join Resonant’s Biorepository division and expand its European capabilities.